Aptamer Group publishes new Corporate Presentation and Investor Factsheet

Aptamer Group

Aptamer Group plc (LON:APTA), the leading developer of next generation synthetic binders delivering innovation to the life science industry, has announced that it has published a new corporate presentation and investor factsheet.

The corporate presentation outlines Aptamer’s strategy, operational progress and financial performance, offering a comprehensive overview of the Group’s growth potential. Complementing this, the investor factsheet provides a succinct two-page summary, focused on highlighting key operational and financial metrics to support investors in their evaluation of the Group.

No new material information has been disclosed in either of these publications.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

    Aptamer Group extends Unilever collaboration for deodorant Optimers

    Aptamer Group has secured additional paid work from Unilever under their existing collaboration, advancing Optimers as deodorant actives with expanded stability testing ahead of on‑person trials.

    Aptamer Group raises £2.0 million in share placing

    Aptamer has raised £2.0 million (before expenses) by placing 666,666,666 new ordinary shares at 0.3 p each, representing 25.1 per cent of its enlarged issued share capital. The proceeds will accelerate commercialisation of the Optimer® platform, support in-house manufacturing, launch new biomarker services and develop AI-driven aptamer discovery.

    Aptamer Group raises £2m to fund growth

    Aptamer Group plc has raised £2.0 million (before expenses) via a placing of new ordinary shares at 0.3p per share, representing a 21.1% discount.

    Aptamer advances liver fibrosis therapy with targeted gene delivery

    Aptamer Group has identified a novel target using its Optimer® platform to deliver gene therapy directly to liver scarring cells.

    Aptamer signs licensing deal for Optimer®-Fc diagnostic reagent

    Aptamer Group has entered a funded development and licensing agreement with a global life sciences company to create an Optimer®-Fc reagent for diagnostic kits. The deal includes royalties on future sales, supporting Aptamer’s recurring revenue growth.

    Aptamer expands odour control collaboration with Unilever

    Aptamer Group plc has partnered with Unilever for a second Optimer program, aiming to innovate body odour control solutions in the personal care market.

      Search

      Search